losartan

losartan
Drug name	Losartan
Tradename	Cozaar, Hyzaar (combination)
Routes of administration	Oral
Class	Angiotensin II receptor blocker
Legal us	Rx-only

losartan is an angiotensin II receptor antagonist used primarily in the management of hypertension, heart failure, and nephropathy associated with diabetes. It is prescribed worldwide and appears on essential medicines lists, having been developed and brought to market through pharmaceutical research and regulatory review. Clinical use involves collaboration among specialists in cardiology, nephrology, and primary care across health systems.

Medical uses

Losartan is indicated for the treatment of hypertension in adults and children, management of heart failure symptoms and reduction of stroke risk in selected populations, and slowing progression of diabetic nephropathy. In hypertension management, guidelines from groups such as the American Heart Association, European Society of Cardiology, National Institute for Health and Care Excellence recommend angiotensin pathway blockade for patients with concurrent myocardial infarction, stroke, or chronic kidney disease. For diabetic nephropathy, recommendations reference trials sponsored by institutions like the National Institutes of Health and conducted at centers such as Mayo Clinic and Cleveland Clinic. In heart failure, professional bodies including the American College of Cardiology and European Society of Cardiology include angiotensin II receptor blockers among options alongside therapies evaluated in studies led by researchers at Harvard Medical School and Johns Hopkins University.

Adverse effects

Common adverse effects reported in clinical trials and pharmacovigilance include dizziness, upper respiratory infections, and hyperkalemia, with monitoring advised by clinicians affiliated with hospitals like Massachusetts General Hospital and Mount Sinai Health System. Less common but serious reactions such as angioedema and renal impairment have been documented in postmarketing surveillance overseen by agencies including the Food and Drug Administration and the European Medicines Agency. Case reports in the literature from institutions such as King's College London and University of Toronto describe cutaneous and hypersensitivity reactions, informing safety communications from manufacturers and regulators.

Pharmacology

Losartan acts as a selective antagonist at the angiotensin II type 1 (AT1) receptor, a target characterized in molecular work from research groups at Stanford University, University of California, San Francisco, and Max Planck Institute. By blocking AT1 receptors, it inhibits angiotensin II–mediated vasoconstriction and aldosterone release, mechanisms explored in foundational studies from laboratories at University of Cambridge and Imperial College London. Losartan’s active metabolite contributes to pharmacodynamic effects measured in clinical pharmacology trials conducted at centers like University of Pennsylvania and Duke University.

Pharmacokinetics

Losartan is absorbed after oral administration, undergoes first-pass hepatic metabolism via cytochrome P450 enzymes, and is converted to an active carboxylic acid metabolite; these metabolic pathways were characterized in studies at Karolinska Institutet and University of Tokyo. The compound shows protein binding and a half-life that supports once- or twice-daily dosing regimens studied in pharmacokinetic trials at University of Michigan and University of Cambridge. Excretion and elimination parameters have been reported in population studies involving cohorts from Johns Hopkins University and University College London.

Interactions

Losartan interacts with agents that affect the renin–angiotensin–aldosterone system, potassium-sparing diuretics, and nonsteroidal anti-inflammatory drugs; interaction profiles are detailed in compendia produced by organizations such as American Society of Health-System Pharmacists and databases maintained at National Library of Medicine. Co-administration with potassium supplements or drugs used in oncology trials at institutions like Dana-Farber Cancer Institute may increase hyperkalemia risk, while concomitant use with cytochrome P450 inhibitors reported in studies at University of California, Los Angeles can alter losartan metabolism. Recommendations for monitoring and adjustment derive from consensus statements from bodies including the European Medicines Agency and Food and Drug Administration.

Dosage and administration

Typical adult dosages are informed by randomized controlled trials conducted at centers such as Brigham and Women's Hospital and Vanderbilt University Medical Center, with starting doses commonly 50 mg once daily and adjustments based on blood pressure response and tolerability. Lower initiation doses may be used in populations studied at pediatric centers like Children's Hospital of Philadelphia and dose titration follows protocols referenced in guidelines from the British Hypertension Society and National Heart, Lung, and Blood Institute. Combination formulations with hydrochlorothiazide are marketed and dosed according to clinical trial data submitted to regulators including the European Medicines Agency.

History and society

Losartan was developed by pharmaceutical researchers and approved following clinical trials and regulatory review; its development involved collaborations among industry and academic partners similar to other drugs brought to market after evaluation by the Food and Drug Administration and European Medicines Agency. It has been the subject of patent litigation and generic market entry events chronicled in reports by legal institutions such as the United States Court of Appeals and trade analyses from organizations like the World Health Organization. Global access, pricing, and inclusion on essential medicines lists have been discussed in policy forums hosted by entities including the World Health Organization, World Bank, and United Nations.

Category:Angiotensin II receptor blockers